EarlySight announces strategic collaboration with RetinAI to enhance clinical Insights from its Cellularis® Retinal Imaging Platform

Geneva, Switzerland - [05/12/2025] - EarlySight SA (“EarlySight”), a Swiss medtech company pioneering cellular-level retinal imaging and biomarkers, is pleased to announce a strategic collaboration with Ikerian AG (“Ikerian”) - the parent company of RetinAI U.S. Inc. (“RetinAI”) - to integrate EarlySight’s Cellularis^® imaging system with RetinAI’s AI-driven clinical workflow and data analysis platform, RetinAI Discovery^®. This news is released during the FLORetina ICOOR 2025 event where both Earlysight and Ikerian are in attendance.

This collaboration combines EarlySight’s breakthrough imaging technology based on adaptive optics - enabling the visualization of microscopic retinal structures - with RetinAI’s advanced, multimodality data management platform in conjunction with the company’s advanced analytics using AI. Together, the two Swiss innovators aim to deliver unprecedented clinical insights to ophthalmologists, researchers, and pharmaceutical partners working to combat vision loss caused by diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy.

“Integrating Cellularis^® with RetinAI’s Discovery^® platform represents a major step toward our vision of redefining how retinal diseases are detected and monitored,” said Timothé Laforest, Chief Executive Officer of EarlySight. “By coupling our cellular-level imaging capabilities with AI-powered data intelligence, we can empower clinicians with deeper, faster, and more accessible insights.”

“We are excited to support EarlySight in bringing a new generation of precision imaging into clinical and research workflows,” added Dr. Carlos Ciller, Chief Executive Officer and Co-Founder of RetinAI. “This integration perfectly aligns with our mission to harness multimodality data and artificial intelligence to improve outcomes for patients affected by vision-threatening diseases.”

The partnership will enable joint research and pharmaceutical collaborations, enabling automated image interpretation, longitudinal tracking, and disease progression modeling. The combined solution aims to set a new benchmark in retinal imaging and analytics - bridging the gap between early diagnosis, treatment monitoring, and personalized care.

About EarlySight

EarlySight SA is a Swiss medical technology company pioneering cellular-level retinal imaging. A spin-off from the Swiss Federal Institute of Technology (EPFL), EarlySight’s Cellularis® platform enables clinicians and researchers to detect and monitor retinal diseases at their earliest stages, empowering a new standard of care in ophthalmology.
More information: www.earlysight.com

About Ikerian AG and RetinAI Inc. U.S

Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc. (‘Ikerian’, ‘RetinAI’ and, together, ‘the company’), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. A commercial stage company with growing sales from RetinAI Discovery®, RetinAI has established collaborations and partnerships with leading ophthalmology clinical networks and pharmaceutical companies. About Ikerian AG www.ikerian.com and RetinAI Inc. US www.retinai.com 

Media Contact - EarlySight SA
Email: info@earlysight.com

Media Contact - Investor Relations at Ikerian AG / RetinAI U.S. Inc.
Email: media@retinai.com

Download the Press Release Document here

‍